ECHA’s 2026 Regulatory Challenges

The European Chemicals Agency’s 2026 update of Key Areas of Regulatory Challenge represents a significant evolution in the EU’s scientific and regulatory expectations for chemical safety. The document reflects ECHA’s expanded mandate under the Common Data Platform on Chemicals (Regulation (EU) 2025/2455) and the Water Protection Directives (Directive (EU) 2026/805), and it sets out a research and regulatory agenda that will directly influence REACH, CLP, BPR, and cross‑regulatory hazard and risk assessment practices.

ECHA states that “the needs for further research and knowledge are organised in five areas”, each of which introduces new technical requirements for industry, researchers, and regulatory professionals.

1. Mechanistic Hazard Identification for the Most Harmful Chemicals

ECHA highlights persistent scientific gaps in understanding neurotoxicity, immunotoxicity, and endocrine disruption. While endocrine disruptors now have harmonised hazard classes under CLP, neurotoxicity and immunotoxicity remain embedded within broader endpoints (STOT SE/RE and reproductive toxicity), creating structural limitations for regulatory decision‑making.

1.1 Neurotoxicity: AOP‑Anchored Mechanistic Evidence

The report emphasises that “there is a need to gain a better understanding of the toxicity mechanisms behind these effects and to develop suitable test methods.” This includes:

• Development of new AOPs and refinement of existing ones

• Establishing molecular initiating events (MIEs) and key events (KEs) with temporal and spatial resolution

• Linking NAM outputs to regulatory‑relevant adverse outcomes

The current AOP landscape for developmental neurotoxicity (DNT) and adult neurotoxicity (ANT) is described as “rudimentary and/or described at such high level”, limiting the regulatory applicability of NAMs.

1.2 Reference Chemicals for NAM Validation

ECHA stresses the need for systematically curated positive and negative reference chemicals. The agency notes that NAMs “lack extensive testing with systematically selected positive and negative reference chemicals”, which is a barrier to validation and regulatory acceptance.

1.3 DNT In‑Vitro Battery (IVB) Development

The DNT IVB requires:

• Increased data density

• Additional mechanistic assays

• Clarification of whether assays predict DNT, ANT, or both

ECHA highlights uncertainty around dual‑purpose assays, noting that many cellular processes “are not only present in the developing nervous system but are also found in the adult nervous system.”

1.4 Early‑Stage ANT Battery Development

Unlike DNT, ANT NAM development is significantly underdeveloped. ECHA calls for foundational work to identify AOPs, mechanistic assays, and prototype battery structures.

2. Environmental Chemical Pollution: Advanced Fate, Exposure, and Biodiversity Assessment

ECHA identifies chemical pollution as a major driver of biodiversity loss. The report expands environmental research needs across several domains:

2.1 Persistence, Bioaccumulation, and Mobility

Regulators require improved:

• In vitro and in silico methods for persistence assessment

• Bioaccumulation modelling beyond traditional BCF/BAF metrics

• Mobility assessment tools for highly polar and ionisable substances

2.2 Biodiversity and Non‑Bee Pollinators

ECHA emphasises the need to understand sensitivity of non‑bee pollinators to biocidal active substances — a gap in current ecotoxicological frameworks.

2.3 Resistance to Biocides

The report introduces a new research area on resistance development, noting the need for mechanistic and predictive models.

2.4 Monitoring and Environmental Impact Valuation

ECHA calls for improved monitoring of substances such as siloxanes and for methodologies to quantify environmental impacts, including biodiversity loss.

3. Transition Away from Animal Testing: Validation and Regulatory Integration of NAMs

ECHA reinforces that the shift away from animal testing must not compromise protection standards. Key technical areas include:

• In vitro and in silico ADME

• Physiologically‑Based Kinetic (PBK) models

• Short‑ and long‑term fish toxicity NAMs

• Carcinogenicity NAMs

The report notes that NAMs are “unlikely to be considered equivalent for any of the REACH or BPR information requirements” without robust validation, meaning hybrid evidence strategies will dominate in the near term.

4. Chemical Data Availability: Substance Identity, Analytical Methods, and Data Infrastructure

Despite extensive EU data generation, ECHA identifies major gaps in:

• Substance identity and composition

• Polymers and polymer grouping

• Micro‑ and nano‑materials

• Analytical methods for restricted and authorised substances

ECHA warns that analytical method availability “can limit the efficiency of chemical management”, signalling increased enforcement pressure.

The Common Data Platform will further raise expectations for data completeness, harmonisation, and cross‑regulatory consistency.

5. Circularity and Safe Materials: Waste‑Stage Emissions and Emerging Contaminants

ECHA’s responsibilities under the Batteries Regulation and Packaging and Packaging Waste Regulation introduce new technical requirements:

• Characterisation of waste‑stage emissions

• Assessment of pyrolysis‑derived materials

• Identification of emerging contaminants in renewable feedstocks

• Economic valuation of environmental impacts

The report states that “to promote circularity it is crucial to address knowledge gaps in chemical emissions from the waste stages”, signalling a shift toward lifecycle‑based risk assessment.

Technical Implications for Industry and Compliance Professionals

The 2026 update signals a regulatory environment that will demand:

• Mechanistic toxicology integrated into hazard assessment

• NAM‑ready dossiers with transparent validation logic

• Advanced environmental fate and biodiversity modelling

• Stronger analytical method justification

• Lifecycle‑based risk assessment frameworks

• Cross‑regulatory data harmonisation under OSOA

Organisations that fail to adapt will face dossier challenges, compliance delays, and increased regulatory scrutiny.

If your organisation needs support interpreting these technical requirements, integrating NAMs, strengthening toxicological justification, or preparing for OSOA‑aligned data expectations, ChemTox Compliance can help.

info@chemtoxcompliance.com